Precision AQ

What do 100 practicing HCPs really think about cost, coverage, and brand interactions in 2025? Their answers might surprise you, and reshape your strategy.

Our most recent report reveals how HCPs are making prescribing decisions in 2025, from out-of-pocket costs to digital touchpoints, new data shows what’s shaping HCP behavior and how brands must adapt.

The economic burden of rare diseases is rapidly growing, with more than half of the novel therapeutics approved in 2023 were for rare disease. In order to secure optimal access for rare disease therapies, manufacturers should consider engaging with payers early in development to understand their priorities. Learn about our 5 tips to help patients access your rare disease therapy.

Digital opinion leaders are reshaping how treatment narratives take hold. But not every voice carries weight. Learn how to spot the ones actually influencing HCP conversations and clinical decisions.

The economic burden of rare diseases is growing, with over half of 2023's new therapeutics targeting them. Engage with payers early to ensure optimal access. Discover our 5 key steps to help patients access your rare disease therapy.

Precision medicine is entering a defining era — a time when discovery meets delivery. At The Institute@Precision, we share insights from the experts navigating this shift, beginning with a deep dive into Antibody–Drug Conjugates (ADCs).